GlassScriptPhysician profile
Bobby Niemann
NPI 1275595985
$4,657.01
in general payments reported to CMS, 2019-2025
39 companies · $1,080 in 2025
The $1,080 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $59.48 · 2022: $230 · 2023: $1,385 · 2024: $1,902 · 2025: $1,080.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,367.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $771.39 | 2021-2025 | |
| Pfizer INC. | $481.27 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $391.27 | 2023-2025 | Ingrezza, Ongentys |
| Lundbeck LLC | $330.69 | 2022-2025 | Vyepti, Rexulti |
| Biogen, INC. | $250.79 | 2022-2025 | Vumerity, Tysabri, Skyclarys |
| Lilly USA, LLC | $223.07 | 2024-2025 | Kisunla, Amyvid, Emgality |
| Genentech USA, INC. | $211.31 | 2024-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Ucb, INC. | $205.65 | 2023-2025 | Zilbrysq, Fintepla, Rystiggo |
| Celgene Corporation | $192.06 | 2023-2025 | Zeposia |
| Alexion Pharmaceuticals, INC. | $182.18 | 2023-2025 | Ultomiris |
| Argenx US, INC. | $172.22 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Impel Pharmaceuticals INC. | $153.72 | 2022-2023 | Trudhesa |
| Emd Serono, INC. | $119.05 | 2023-2025 | Mavenclad |
| Tanabe Pharma America, INC. | $78.84 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $76.96 | 2023 | Andexxa |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bobby Niemann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.